Noninvasix is building a precision oximetry platform that safely and accurately measures venous oxygen saturation in the brains of infants in neonatal intensive care units. Its optoacoustic sensor provides real-time data on cerebral blood oxygenation, addressing brain hypoxia, a condition responsible for 23 percent of global neonatal deaths and costing the U.S. healthcare system over $7 billion annually. By enabling clinicians to detect inadequate oxygen supply quickly, the technology aims to improve decision-making and infant outcomes. The company is currently advancing product development and pursuing FDA clearance with fresh capital from its latest financing. Noninvasix describes its recent $2 million seed round as oversubscribed, signaling strong investor interest. While revenue and user metrics have not been disclosed, the new funds extend its runway for regulatory work and commercialization planning. Support from strategic backers such as Philips underscores potential clinical adoption paths. Overall, the firm is positioned to bring a first-in-class, non-invasive monitoring solution to maternal-fetal health.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2021